Septerna, inc. SEPN.US Overview
SEPN AI Analysis & Strategy
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
SEPN Current Performance
-0.26%
Septerna, inc.
0.98%
Avg of Sector
0.83%
S&P500
SEPN Key Information
SEPN Financial Forecast
Unit : USD
SEPN Earnings Table
SEPN Profile
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.
Price of SEPN
SEPN FAQ
When is SEPN's latest earnings report released?
The most recent financial report for Septerna, inc. (SEPN) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SEPN’s short-term business performance and financial health. For the latest updates on SEPN’s earnings releases, visit this page regularly.
How much debt does SEPN have?
As of the end of the reporting period, Septerna, inc. (SEPN) had total debt of 25.03M, with a debt ratio of 0.06. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company’s capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does SEPN have?
At the end of the period, Septerna, inc. (SEPN) held Total Cash and Cash Equivalents of 210.95M, accounting for 0.49 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does SEPN go with three margins increasing?
In the latest report, Septerna, inc. (SEPN) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -11,831.05%%, and net margin of -9,806.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SEPN’s profit trajectory and future growth potential.
What are the PEG ratio and PE ratio of SEPN?
The latest valuation data shows Septerna, inc. (SEPN) has a Price-To-Earnings (PE) ratio of -2.96 and a Price/Earnings-To-Growth (PEG) ratio of 0.13. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.